Pfizer has developed a new an experimental compound, called GRN-529 for use with Fragile X patients. Some positive results have been shown in social behaviour of mice.
Full story here –
Notes – Fragile X
“Fragile X Syndrome is the most common cause of inherited intellectual disability and the most common known genetic cause of autism. It is a condition which can have impact on individuals and families in various ways and degrees of severity.
Fragile X is found in all races and at all socio-economic levels. Latest statistics indicate 1 in 3600 males and 1 in 4000- 6000 females are affected and that approximately 1 in 260 females are carriers.”
Glutamate receptors are synaptic receptors located primarily on the membranes of neuronal cells. Glutamate is one of the 20 amino acids used to assemble proteins, so is abundant in many areas of the body, but it also functions as a neurotransmitter and is particularly abundant in the nervous system. Glutamate receptors are responsible for the glutamate-mediated postsynaptic excitation of neural cells, and are important for neural communication, memory formation, learning, and regulation. Furthermore, glutamate receptors are implicated in the pathologies of a number of neurodegenerative diseases due to their central role in excitotoxicity and their prevalence throughout the central nervous system.